EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, VTGN: Vistagen Therapeutics Inc

10 Nov 25 11:31
LAST:

3.950

CHANGE:
 0.04		OPEN:
3.990		HIGH:
4.100		ASK:
0.800		VOLUME:
117.2K
CHG(%):
1.00		PREV:
3.990		LOW:
3.860		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Nov 253.9904.1003.8603.950117.2K
07 Nov 253.9504.0203.6903.990595.5K
06 Nov 254.2304.2303.9704.020270.6K
05 Nov 254.1504.2854.0504.180283.5K
04 Nov 254.1804.3004.0604.070402.3K
03 Nov 254.2404.6504.1304.2401.17M
31 Oct 253.7703.9703.7113.940231.6K
30 Oct 253.9604.0703.6903.750340.1K
29 Oct 253.9504.0903.7963.960547.1K
28 Oct 253.8804.1003.8004.050433.4K

COMPANY PROFILE

Name:Vistagen Therapeutics Inc
About:Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:343 Allerton Avenue, South San Francisco, CA, United States, 94080
Website:https://www.vistagen.com
CUSIP:92840H103
CIK:0001411685
ISIN:US92840H2022
FIGI:BBG000BB33L9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:4.042.3%
MA10:4.021.6%
MA20:4.062.8%
MA50:3.755.5%
MA100:3.2122.9%
MA200:2.8638.3%
STO9:22.22
STO14:22.22
RSI14:42.63
WPR14:-59.18
MTM14:-0.15
ROC14:-0.04 
ATR:0.31 
Week High:4.6517.7%
Week Low:3.697.0%
Month High:4.6517.7%
Month Low:3.6938.3%
Year High:4.6517.7%
Year Low:1.90107.9%
Volatility:22.17 

RECENT SPLITS

Date Ratio
07 Jun 20231-30
14 Aug 20141-20